Czech Republic
France
Germany
Norway
Netherlands
Spain
Turkey
United KingdomUpdates
SUB-TYPE:
Platinum Jubilee Service Information
To help keep our customers informed of changes to our service, we have published our Platinum Jubilee Bank Holiday opening hours.
For more information please click here
SUB-TYPE:
Alliance Healthcare marks £100k raised for Vitamin Angels UK
Alliance Healthcare marks £100,000 raised for Vitamin Angels UK to support its purpose in improving access to essential nutrition for mothers and children in the UK and around the world.
Yesterday, team members across Alliance Healthcare joined a virtual event called “Around the World” to celebrate the amazing £100,000 fundraising milestone. Marie Evans, Managing Director congratulated the teams who have completed cycle challenges, organised football matches and multiple fundraising events in aid of the charity.
Vitamin Angels UK provided an interactive virtual tour of the villages across the world where funds raised have helped create healthier futures. Over the last four years of the partnership, Alliance Healthcare and Vitamin Angels have reached the lives of over 468,600 children.
Sam Unsworth, CSR Champion for Alliance Healthcare closed the event and said: “We should be really proud of our fundraising efforts to support our charity partnership with Vitamin Angels. Today, was a moment to reflect on our achievement and hear more from the charity. This has really spurred us on to create even more impactful fundraising events. Together we will continue to make a meaningful difference for those that need it most.”
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Drug Caution In Use - Zovirax I.V. 500mg
GlaxoSmithKline UK Ltd have informed the MHRA that an incorrect version of the Summary of Product Characteristics section 4.2 and the Patient Information Leaflet is inside the sealed pack, and contains unapproved text.
MHRA drug alert link:
Pip code | Product description | Supplier | Batch Numbers |
489633 | ZOVIRAX IV VIAL 500MG | GLAXOSMITHKLINE UK LTD | 9G4B TC8E-A 6V8W GN8S J69C B35J |
This is a caution in use only we are not accepting stock returns.
Further Information
If you have any questions, please contact GSK UK Ltd Medical Information Department on 0800 221 441 or email: ukmedinfo@gsk.com
SUB-TYPE:
Prince Charles praises pharmacy sector’s ‘dedication and professionalism’ during Covid-19 pandemic
Prince Charles has praised the “dedication and professionalism of pharmacy staff” at an event held in London to celebrate the work of community pharmacists during the Covid-19 pandemic.
His Royal Highness The Prince of Wales hosted a special event this week at St. James’s Palace State Apartments to celebrate Community Pharmacists.
200 community pharmacy members and other honoured guests, including Our Managing Director, Marie Evans had the privilege of attending.
Speaking about the event, Marie said: “Community pharmacy deserve this recognition, they continued to support UK patients at every moment of the pandemic – and beyond. Their unwavering dedication is something to be admired and celebrated. This has been a very fitting celebration for our remarkable community pharmacists and their teams.”
Read more about the event in the below link:
SUB-TYPE: CLASS 2 RECALL
Class 2 Recall - Accupro 5mg, 10mg, 20mg, 40mg film-coated tablets
Pfizer Limited are recalling all batches of Accupro 5mg, 10mg, 20mg, 40mg film-coated tablets as a precautionary measure.
MHRA drug alert link:
Pip code | Product description | Supplier | Batch Numbers |
258764 | ACCUPRO TAB 5MG X 28 | PFIZER LTD | FJ7218 EY5501 EA9306 |
258780 | ACCUPRO TAB 10MG X 28 | PFIZER LTD | FK8588 EP6753 |
258822 | ACCUPRO TAB 20MG X 28 | PFIZER LTD | FF8046 FF8045 EA9304 DK4190 |
2035467 | ACCUPRO TAB 40MG X 28 | PFIZER LTD | FK9758 EP1602 CW7390 |
Further Information
For medical information enquiries, please contact Pfizer Medical Information Department on 01304 616161.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.
SUB-TYPE:
Alcura Rated “Good” in CQC Report
Alcura receive “Good” in its recent Care Quality Commission (CQC) report a high standard in a competitive market. “This accreditation will go a long way in demonstrating to our patients, future patients, the NHS and manufacturers, the high-level of patient care we deliver at Alcura. As a purpose led organisation, we are dedicated to patient care, so to receive this recognition for our safety is a fantastic reflection of our knowledge and expertise in homecare,” said Pip Reid, Head of Nursing, Alcura.
Alcura received the second highest possible score in its recent CQC report, following the recent unannounced inspection at Alcura House. CQC, the independent regulator of health and social care in England, completed an intense two-day inspection at the Alcura site in Northampton, in February, and recently published the report on its website.
Alcura was inspected as part of the Community Services pillar and its support to care in patient homes, where there is a big emphasis on safety.
The CQC Inspection Report is based on a combination of what the organisation finds when they undertake the inspection, the information from its ongoing monitoring of data about services and information handed by the provider, patients, the public and other organisation. The report covers five questions and areas within the services provided across: Safety, Effectiveness, Caring, Responsiveness and Leadership.
CQC findings conclude that: “We rated the service as good because [..] The service had enough staff to care for patients and keep them safe. Alcura House had a pool of regular bank staff and did not use agency staff. Patients therefore received consistent care from the same nurses. All nursing staff had training in key clinical skills which had been tested through competency assessments.”
Other findings include: “Staff provide good care and treatment [..] Staff treated patients with compassion and kindness [..] Staff understood how to protect patients from abuse [..] Staff assessed risks to patients, acted on them and kept good care records.”
At the time of this inspection, Alcura had 1,252 clinical interactions per month and was supporting 45,000 registered patients. Alcura is committed to maintaining the high standards of patient safety and to identify and implement steps required to reach the highest CQC score - outstanding.
SUB-TYPE: CLASS 2 RECALL
Class 2 Recall - Sodium bicarbonate 1.26% Solution for infusion 500ml
Fresenius Kabi Limited are recalling the below batch of product as a precautionary measure due to the identification of particles in the solution for infusion, following routine batch analysis and subsequent batches manufactured on the same filling line. The company’s investigation indicates that he particles appear to originate from the interaction between the equipment and the packaging material during the filling process. The integrity of the packaging and sterility of the product are not compromised.
MHRA drug alert link:
Pip code | Product description | Supplier | Batch Number |
ALLIANCE DO NOT STOCK | SODIUM BICARBONATE 1.26% SOLUTION FOR INFUSION 500ML | FRESENIUS KABI LIMITED | 22BC01 |
Further Information
For more information, medical or supply enquiries, please contact 01928 533 758 FK.Complaints-UK@fresenius-Kabi.com or Customer.Services-UK@Fresenius-Kabi.com
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
SUB-TYPE: CLASS 2 RECALL
Class 2 Recall - Paroxetine 40mg Film Coated X 30 Tablets
Crescent Pharma Limited are recalling the below batch of product as a precautionary measure due to out of specification results for dissolution during routine stability testing.
MHRA drug alert link:
Pip code | Product description | Supplier | Batch Numbers |
8150096 | PAROXETINE TAB 40MG X 30 | CRESCENT PHARMA LTD | 06309 |
Further Information
For more information, medical or supply enquiries, please contact 01256 772730
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.
SUB-TYPE:
Early May 2022 Bank Holiday Opening Hours now available
To help keep our customers informed of changes to our service, we have published our Early May 2022 Bank Holiday opening hours.
Find out more information by clicking here.
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Drug Caution In Use - Depo-Medrone with Lidocaine 40 mg/mL (1 mL and 2 mL vials – single vial preparations)
Pfizer Limited have informed the MHRA that an outdated version of the Patient Information Leaflet (PIL) has been included in the packaging of the above mentioned batches of Depo-Medrone with Lidocaine (Methylprednisolone acetate and Lidocaine hydrochloride) 40 mg/mL 1 mL and 2 mL vials (single vial presentations) to the UK market.
MHRA drug alert link:
Pip code | Product description | Supplier | Batch Numbers |
2343036 | DEPO MEDRONE LIDOCAIN 40MG/ML, 1ML | PFIZER LTD | EL4771 FK6842 |
294892 | DEPO MEDRONE LIDOCAIN 40MG/ML, 2ML | PFIZER LTD | EK3997 FK6089 FN9557 |
This is a caution in use only we are not accepting stock returns.
Further Information
If you have any questions, please contact Pfizer Medical Information Department on 01304 616161